14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CHNR vs ABCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, China Natural Resources, Inc. (CHNR) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHNR carries a Unified Composite Score of 43.4/100 (HOLD) at $2.98 (7.8x Forward P/E, 0.0% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin).
Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. CHNR 43.4/100 HOLD), CHNR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (-24.0% vs. +18.8% YoY).
Technical & Structure Timing Caution: CHNR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHNR vs ABCL. Trailing 12-month operating profitability (CHNR 0.0% vs ABCL -298.0%) and valuation multiples (CHNR 7.8x vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.4B market capitalization and -298.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CHNR vs ABCL Key Questions & Quantitative Answers
As of Nov 20, 2026, China Natural Resources, Inc. (CHNR) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHNR carries a Unified Composite Score of 43.4/100 (HOLD) at $2.98 (7.8x Forward P/E, 0.0% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin). Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. CHNR 43.4/100 HOLD), CHNR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (-24.0% vs. +18.8% YoY). Technical & Structure Timing Caution: CHNR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABCL leads the Growth & Scale pillar: CHNR posts -24.0% YoY revenue growth and +0.0% YoY earnings growth on $16M TTM revenue (1.5% gross margin, 0.0% operating margin), compared with ABCL at +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin). On trailing 12-month operating scale, CHNR generates $16M in USD-normalized revenue versus $68M for ABCL. In operating R&D and SG&A reinvestment, CHNR deploys 1.5% of Rev ($246,750) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.
CHNR screens cheaper on headline valuation multiples. CHNR trades at 7.8x Forward P/E, 7.8x Trailing P/E, 0.30x PEG, and 0.2x EV/Revenue (-20.0% EBITDA margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 50.0x EV/Revenue (-48.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHNR (-1.4% ROE) versus ABCL (-14.6% ROE) capital efficiency.
In options market volatility and institutional positioning, CHNR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.15β · 53% Vol realized risk). By comparison, ABCL carries 86.5% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.